Elimination of cancer stem cells

Stem Cell Biology in Health and Disease

Volumn , Issue , 2009, Pages 357-384

  Sagrera, A ^a   Perez Losada J ^b   Perez Caro M ^a   Jimenez R ^c   Sanchez Garcia I ^c   Cobaleda, C ^c  

^a OncoStem Pharma   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cancer stem cells; Chemoresistance; Differentiation therapies; Hedgehog pathway; Notch pathway; Polycomb pathway; PTEN pathway; Self renewal; Targeted therapies; Wnt pathway

Indexed keywords

EID: 84900739914     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-3040-5_16     Document Type: Chapter

References (119)

1. Cobaleda C, Vicente-Duenas C and Sanchez-Garcia I (2007) Cancer Stem Cells. JohnWiley & Sons, Ltd, Chichester
2. Sanchez-Garcia I, Vicente-Duenas C and Cobaleda C (2007) The theoretical basis of cancerstem- cell-based therapeutics of cancer: can it be put into practice? Bioessays 29: 1269-1280
3. Bonnet D and Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737
4. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. (2000) A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 95: 1007-1013
5. Lapidot T, Sirard C, Vormoor J, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988
7. Singh SK, Hawkins C, Clarke ID, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401
8. Li C, Heidt DG, Dalerba P, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037
9. Prince ME, Sivanandan R, Kaczorowski A, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978
10. Dalerba P, Dylla SJ, Park IK, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163
11. OBrien CA, Pollett A, Gallinger S, et al. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115
13. Clarke MF, Dick JE, Dirks PB, et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344
14. Cho RW and Clarke MF (2008) Recent advances in cancer stem cells. Curr Opin Genet Dev 18: 48-53
15. Kelly PN, Dakic A, Adams JM, et al. (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317: 337
16. Virchow R (1855) Editorial. Virchows Arch Pathol Anat Physiol Klin Med 3: 23
17. Cohnheim J (1867) Ueber entzuendung und eiterung. Path Anat Physiol Klin Med 40: 1-79
18. Etzioni R, Urban N, Ramsey S, et al. (2003) The case for early detection. Nat Rev Cancer 3: 243-252
19. Berns A (2005) Stem cells for lung cancer? Cell 121: 811-813
20. Clarke MF (2005) A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 56(Suppl 1): 64-68
21. Hambardzumyan D, Squatrito M and Holland EC (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10: 454-456
22. Lou H and Dean M (2007) Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26: 1357-1360
23. Trumpp A and Wiestler OD (2008) Mechanisms of Disease: cancer stem cells-targeting the evil twin. Nat Clin Pract 5: 337-347
24. Woodward WA, Chen MS, Behbod F, et al. (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104: 618-623
25. Massard C, Deutsch E and Soria JC (2006) Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 17: 1620-1624
26. Blagosklonny MV (2006) Target for cancer therapy: proliferating cells or stem cells. Leukemia 20: 385-391
27. Klonisch T, Wiechec E, Hombach-Klonisch S, et al. (2008) Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 14(10): 450-460
28. Ward RJ and Dirks PB (2007) Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2: 175-189
29. Clarke MF and Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124: 1111-1115
30. Gil J, Stembalska A, Pesz KA, et al. (2008) Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet 49: 193-199
31. Huntly BJ and Gilliland DG (2005) Leukaemia stem cells and the evolution of cancer-stemcell research. Nat Rev Cancer 5: 311-321
32. Smith A (2006) A glossary for stem-cell bioology. Nature doi:10.1038/nature04954
33. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846
34. Croker AK and Allan AL (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12: 374-390
35. Rajasekhar VK and Begemann M (2007) Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25: 2498-2510
36. Li F, Tiede B, Massague J, et al. (2007) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17: 3-14
37. Hermann PC, Huber SL, Herrler T, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323
38. Visvader JE and Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768
39. Chambers AF, Groom AC and MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572
40. Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8: 98-101
41. Ratajczak MZ, Zuba-Surma E, Kucia M, et al. (2006) The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20: 1915-1924
42. Liang Z, Wu T, Lou H, et al. (2004) Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64: 4302-4308
43. Gallacher L, Murdoch B, Wu DM, et al. (2000) Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 95: 2813-2820
44. Perez-Caro M and Sanchez-Garcia I (2006) Killing time for cancer stem cells (CSC): discovery and development of selective CSC inhibitors. Curr Med Chem 13: 1719-1725
45. Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51: 1-28
46. Sell S (2006) Cancer stem cells and differentiation therapy. Tumour Biol 27: 59-70
47. Ohno R, Asou N and Ohnishi K (2003) Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17: 1454-1463
48. Mueller E, Sarraf P, Tontonoz P, et al. (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470
49. Tontonoz P, Singer S, Forman BM, et al. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237-241
50. Taddei A, Roche D, BickmoreWA, et al. (2005) The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6: 520-524
51. Piccirillo SG, Reynolds BA, Zanetti N, et al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765
52. Chiba S (2006) Notch signaling in stem cell systems. Stem Cells 24: 2437-2447
53. Natarajan TG and FitzGerald KT (2007) Markers in normal and cancer stem cells. Cancer Biomark 3: 211-231
54. Roy M, Pear WS and Aster JC (2007) The multifaceted role of Notch in cancer. Curr Opin Genet Dev 17: 52-59
55. Rizzo P, Osipo C, Foreman K, et al. (2008) Rational targeting of Notch signaling in cancer. Oncogene 27: 5124-5131
56. Ruiz i Altaba A (2008) Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets? Cancer Cell 14: 281-283
57. Varjosalo M and Taipale J (2008) Hedgehog: functions and mechanisms. Genes Dev 22: 2454-2472
58. Bar EE, Chaudhry A, Lin A, et al. (2007) Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524-2533
59. Clement V, Sanchez P, de Tribolet N, et al. (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17: 165-172
60. Yauch RL, Gould SE, Scales SJ, et al. (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455: 406-410
61. Peacock CD, Wang Q, Gesell GS, et al. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 104: 4048-4053
62. Watkins DN, Berman DM, Burkholder SG, et al. (2003) Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422: 313-317
63. Kimura H, Ng JM and Curran T (2008) Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13: 249-260
64. Lobo M and Zachary I (2000) Nuclear localization and apoptotic regulation of an aminoterminal domain focal adhesion kinase fragment in endothelial cells [In Process Citation]. Biochem Biophys Res Commun 276: 1068-1074
65. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480
66. Staal FJ, Luis TC and Tiemessen MM (2008) WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 8: 581-593
67. Giuliani N, Morandi F, Tagliaferri S, et al. (2007) Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 67: 7665-7674
68. Tian E, Zhan F, Walker R, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494
69. Katoh M and Katoh M (2007) WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042-4045
70. Barker N and Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014
71. Levine SS, King IF and Kingston RE (2004) Division of labor in polycomb group repression. Trends Biochem Sci 29: 478-485
72. Dimri GP, Martinez JL, Jacobs JJ, et al. (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62: 4736-4745
73. Lessard J and Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260
74. Molofsky AV, Pardal R, Iwashita T, et al. (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425: 962-967
75. Molofsky AV, He S, Bydon M, et al. (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19: 1432-1437
76. Park IK, Qian D, Kiel M, et al. (2003) Bmi-1 is required for maintenance of adult selfrenewing haematopoietic stem cells. Nature 423: 302-305
77. Hemmati HD, Nakano I, Lazareff JA, et al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100: 15178-15183
78. Jacobs JJ, Scheijen B, Voncken JW, et al. (1999) Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13: 2678-2690
79. Iwama A, Oguro H, Negishi M, et al. (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21: 843-851
80. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP, et al. (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19: 1438-1443
81. Janzen V, Forkert R, Fleming HE, et al. (2006) Stem-cell ageing modified by the cyclindependent kinase inhibitor p16INK4a. Nature 443: 421-426
82. Tan J, Yang X, Zhuang L, et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063
83. Nakamura T, Largaespada DA, Lee MP, et al. (1996) Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 12: 154-158
84. Fischbach NA, Rozenfeld S, Shen W, et al. (2005) HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo. Blood 105: 1456-1466
85. Yuan TL and Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510
86. Keniry M and Parsons R (2008) The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485
87. Stambolic V, MacPherson D, Sas D, et al. (2001) Regulation of PTEN transcription by p53. Mol Cell 8: 317-325
88. Howes AL, Chiang GG, Lang ES, et al. (2007) The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cellmotility and growth in three-dimensional cultures. Mol Cancer Ther 6: 2505-2514
89. Garlich JR, De P, Dey N, et al. (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68: 206-215
90. Yaguchi S, Fukui Y, Koshimizu I, et al. (2006) Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98: 545-556
91. Chen JS, Zhou LJ, Entin-Meer M, et al. (2008) Characterization of structurally distinct, isoform-selective phosphoinositide 3-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 7: 841-850
92. Garcia-Echeverria C and Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526
93. Yilmaz OH, Valdez R, Theisen BK, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482
94. Guo W, Lasky JL, Chang CJ, et al. (2008) Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453: 529-533
95. Helleday T, Petermann E, Lundin C, et al. (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204
96. Vucic D and Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13: 5995-6000
97. Yang L, Mashima T, Sato S, et al. (2003) Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63: 831-837
98. Eckelman BP, Salvesen GS and Scott FL (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988-994
99. Wang CY, Mayo MW, Korneluk RG, et al. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683
100. Harley CB (2008) Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179
101. Shay JW and Wright WE (2006) Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 5: 577-584
102. Hombach-Klonisch S, Paranjothy T, Wiechec E, et al. (2008) Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp 56: 165-180
103. Akiyama M, Hideshima T, Shammas MA, et al. (2003) Effects of oligonucleotide N3-P5 thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 63: 6187-6194
104. Wang ES, Wu K, Chin AC, et al. (2004) Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103: 258-266
105. Gellert GC, Dikmen ZG, Wright WE, et al. (2006) Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 96: 73-81
106. Gomez-Millan J, Goldblatt EM, Gryaznov SM, et al. (2007) Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int J Radiat Oncol Biol Phys 67: 897-905
107. Dikmen ZG, Gellert GC, Jackson S, et al. (2005) In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65: 7866-7873
108. Ozawa T, Gryaznov SM, Hu LJ, et al. (2004) Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-oncology 6: 218-226
109. Djojosubroto MW, Chin AC, Go N, et al. (2005) Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42: 1127-1136
110. Dikmen ZG, Wright WE, Shay JW, et al. (2008) Telomerase targeted oligonucleotide thiophosphoramidates in T24-luc bladder cancer cells. J Cell Biochem 104: 444-452
111. Asai A, Oshima Y, Yamamoto Y, et al. (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63: 3931-3939
112. Cortez-Gonzalez X and Zanetti M (2007) Telomerase immunity from bench to bedside: round one. J Transl Med 5: 12
113. Parmar K, Mauch P, Vergilio JA, et al. (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104: 5431-5436
114. Tang C, Ang BT and Pervaiz S (2007) Cancer stem cell: target for anti-cancer therapy. Faseb J 21: 3777-3785
115. Lagasse E (2008) Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Ther 15: 136-142
116. Herranz M and Sanchez-Garcia I (2007) Medical chemistry to spy cancer stem cells from outside the body. Mini Rev Med Chem 7: 781-791
117. Shah K, Jacobs A, Breakefield XO, et al. (2004) Molecular imaging of gene therapy for cancer. Gene Ther 11: 1175-1187
118. Vicente-Duenas C, Voces F, Perez-Caro M, et al. (2005) Improving the development on new cancer treatments: challenges and opportunities. Bentham Science Publishers Ltd., San Francisco, CA
119. Nakamura ES, Koizumi K, Kobayashi M, et al. (2006) RANKL-induced CCL22/ macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 23: 9-18